

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION

ZEJULA (NIRAPARIB)

1 NAME OF THE MEDICINE

ZEJULA (niraparib)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains niraparib tosylate monohydrate equivalent to 100 mg niraparib. Excipients with known effect: Each capsule contains lactose monohydrate. Each capsule shell also contains the colouring agent tartrazine.

Each film-coated tablet contains niraparib tosylate monohydrate equivalent to 100 mg. Excipients with known effect: Each film coated tablet contains lactose monohydrate.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Capsule

Hard capsules have a white body with “100 mg” printed in black ink and purple cap with “Niraparib” printed in white ink.

Tablets

100 mg grey, oval-shaped, film-coated tablet debossed with “100” on one side and “Zejula” on the other.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

ZEJULA is indicated:

- for the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

4.2 DOSE AND METHOD OF ADMINISTRATION

Treatment with ZEJULA should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.

First-line ovarian cancer maintenance treatment

The recommended starting dose of niraparib is 200 mg (two 100 mg capsules or tablets) taken once daily. For patients who weigh ≥ 77 kg and have baseline platelet count $\geq 150,000/\mu\text{L}$, the recommended starting dose of niraparib is 300 mg (three 100 mg capsules or tablets) taken orally once daily.

Recurrent ovarian cancer maintenance treatment

The recommended starting dose is 300 mg (three 100 mg capsules or tablets) taken orally once daily.

Patients should be encouraged to take their dose at approximately the same time each day. Bedtime administration may be a potential method for managing nausea.

The capsules or tablets should be swallowed whole with water. The capsules or tablets should not be chewed or crushed. ZEJULA can be taken without regard to meals (see Section 5.2 PHARMACOKINETIC PROPERTIES).

It is recommended that treatment should be continued until disease progression or unacceptable toxicity.

Missing dose

If patients miss a dose, they should take their next dose at its regularly scheduled time.

Dose adjustments for adverse reactions

To manage adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation. The recommended dose modifications for adverse reactions are listed in Tables 1, 2 and 3.

Table 1: Recommended dose modifications for adverse reactions

| <i>Starting dose</i> | 200 mg/day | 300 mg/day |
|-----------------------|------------------------|-------------|
| First dose reduction | 100 mg/day | 200 mg/day |
| Second dose reduction | Discontinue medication | 100 mg/day* |

*If further dose reduction below 100 mg/day is required, discontinue ZEJULA.

Table 2: Dose modifications for non-haematological adverse reactions

| | |
|---|---|
| Non-haematological CTCAE [‡] \geq Grade 3 adverse reaction that persists despite treatment/prophylaxis ^a | First occurrence: <ul style="list-style-type: none">• Withhold ZEJULA for a maximum of 28 days or until resolution of adverse reaction.• Resume ZEJULA at a reduced dose per Table 1. Second occurrence: <ul style="list-style-type: none">• Withhold ZEJULA for a maximum of 28 days or until resolution of adverse reaction.• Resume ZEJULA at a reduced dose or discontinue per Table 1. |
| CTCAE \geq Grade 3 treatment-related adverse reaction lasting more than 28 days while patient is administered ZEJULA 100 mg/day | <ul style="list-style-type: none">• Discontinue ZEJULA. |

[‡]CTCAE=Common Terminology Criteria for Adverse Events

^aProphylaxis includes, but is not limited to, medications to prevent nausea, vomiting, diarrhoea, constipation, headache, back pain, myalgia, arthralgia, insomnia, decreased appetite, or dry mouth.

Table 3: Dose modifications for haematological adverse reactions

| | |
|---|--|
| <p>Haematologic adverse reactions have been observed during treatment with ZEJULA especially during the initial phase of the treatment. It is therefore recommended to monitor complete blood counts (CBCs) weekly during the first month of treatment and modify the dose as needed. After the first month, it is recommended to monitor CBCs monthly and periodically after this time (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). Based on individual laboratory values, weekly monitoring for the second month may be warranted.</p> | |
| Haematological adverse reaction requiring transfusion or haematopoietic growth factor support | <ul style="list-style-type: none"> For patients with platelet count $\leq 10,000/\mu\text{L}$, platelet transfusion should be considered. If there are other risk factors for bleeding such as co-administration of anticoagulation or antiplatelet medicinal products, consider interrupting these substances and/or transfusion at a higher platelet count. Resume ZEJULA at a reduced dose per Table 1. |
| Platelet count $< 100,000 \mu\text{L}$ | <p>First occurrence:</p> <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100,000/\mu\text{L}$. Resume ZEJULA at same or reduced dose per table 1 based on clinical evaluation. If platelet count is $< 75,000/\mu\text{L}$ at any time, resume at a reduced dose per Table 1. |
| | <p>Second occurrence:</p> <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100,000/\mu\text{L}$. Resume ZEJULA at a reduced dose per Table 1. Discontinue ZEJULA if the platelet count has not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg once daily. |
| Neutrophil $< 1,000/\mu\text{L}$ or Haemoglobin $< 8 \text{ g/dL}$ | <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until neutrophil counts return to $\geq 1,500/\mu\text{L}$ or haemoglobin returns to $\geq 9 \text{ g/dL}$. Resume ZEJULA at a reduced dose per Table 1. Discontinue ZEJULA if neutrophils and/or haemoglobin have not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg once daily. |
| Confirmed diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) | <ul style="list-style-type: none"> Permanently discontinue ZEJULA. |

Elderly

No dose adjustment is necessary for elderly patients (≥ 65 years). There are limited clinical data in patients aged 75 or over.

Renal impairment

No dose adjustment is necessary for patients with mild to moderate renal impairment. There are no data in patients with severe renal impairment or end stage renal disease undergoing haemodialysis; use with caution in these patients, see Section 5.2 PHARMACOKINETIC PROPERTIES.

Hepatic impairment

No dose adjustment is needed in patients with mild hepatic impairment.

For patients with moderate hepatic impairment, the recommended starting dose of ZEJULA is 200 mg once daily, see Section 5.2 PHARMACOKINETIC PROPERTIES.

There are no data in patients with severe hepatic impairment; use with caution in these patients, see Section 5.2 PHARMACOKINETIC PROPERTIES.

Patients with ECOG performance status 2 to 4

Clinical data are not available in patients with ECOG performance status 2 to 4.

Paediatric population

The safety and efficacy of ZEJULA in children and adolescents below 18 years of age have not yet been established. No data are available.

4.3 CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 LIST OF EXCIPIENTS.

Breast-feeding (see Section 4.6 FERTILITY, PREGNANCY AND LACTATION).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Haematological adverse reactions

Haematological adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported in patients treated with niraparib. In the PRIMA and NOVA studies, patients eligible for ZEJULA therapy had the following baseline haematological parameters: absolute neutrophil count (ANC) $\geq 1,500$ cells/ μL ; platelets $\geq 100,000$ cells/ μL and haemoglobin ≥ 10 g/dL (PRIMA) or ≥ 9 g/dL (NOVA) prior to therapy.

In the PRIMA study, the overall incidence of Grade ≥ 3 thrombocytopenia, anaemia and neutropenia in clinical and/or laboratory findings were reported in 39%, 31%, and 21% of patients receiving ZEJULA respectively. Discontinuation due to thrombocytopenia, anaemia and neutropenia occurred in 4%, 2% and 2% of patients, respectively.

In patients who were administered a starting dose of ZEJULA based on baseline weight or platelet count, Grade ≥ 3 thrombocytopenia, anaemia and neutropenia were reported in 15%, 23% and 10% of patients

receiving ZEJULA, respectively. Discontinuation due to thrombocytopenia, anaemia and neutropenia occurred in 3%, 3%, and 2% of patients, respectively.

In the NOVA study,

Grade ≥ 3 thrombocytopenia, anaemia and neutropenia were reported in 29%, 25% and 20% of patients receiving ZEJULA, respectively. Discontinuation due to thrombocytopenia, anaemia, and neutropenia occurred in 3%, 1%, and 2% of patients, respectively.

If a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption, ZEJULA should be discontinued.

Test complete blood counts weekly for the first month, followed by monthly monitoring for the next 10 months of treatment and periodically after this time to monitor for clinically significant changes in any haematologic parameter during treatment, see Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Due to the risk of thrombocytopenia, anticoagulants and medicinal products known to reduce the thrombocyte count should be used with caution, see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS).

Myelodysplastic syndrome/acute myeloid leukaemia

Myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), including cases with fatal outcome, have been reported in patients who received ZEJULA (see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)).

In clinical trials, the duration of ZEJULA treatment in patients prior to developing MDS/AML varied from 1 month to > 4 years. The cases were typical of secondary, cancer therapy-related MDS/AML. All patients had received platinum-containing chemotherapy regimens and many had also received other DNA damaging agents and radiotherapy. Some of the patients had a history of bone marrow dysplasia.

For suspected MDS/AML or prolonged haematological toxicities, the patient should be referred to a haematologist for further evaluation. If MDS/AML is confirmed, treatment with ZEJULA, treatment should be discontinued.

Hypertension, including hypertensive crisis

Hypertension, including hypertensive crisis, has been reported with the use of ZEJULA (see Section 4.8 Adverse Effects). Pre-existing hypertension should be adequately controlled before starting ZEJULA treatment. Blood pressure and heart rate should be monitored at least weekly for the first two months, then monthly for the first year and periodically thereafter during treatment with ZEJULA.

Hypertension should be medically managed with antihypertensive medicinal products as well as adjustment of the ZEJULA dose (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION), if necessary. In the clinical programme, blood pressure measurements were obtained on Day 1 of each 28-day cycle while the patient remained on ZEJULA. In most cases, hypertension was controlled adequately using standard antihypertensive treatment with or without ZEJULA dose adjustment, see Section 4.2 DOSE AND METHOD OF ADMINISTRATION. ZEJULA should be discontinued in case of hypertensive crisis or if medically significant hypertension cannot be adequately controlled with antihypertensive therapy.

Posterior Reversible Encephalopathy Syndrome (PRES)

There have been rare reports (0.09% of clinical trial patients) of ZEJULA-treated patients developing signs and symptoms that are consistent with Posterior Reversible Encephalopathy Syndrome (PRES) (see Section 4.8 ADVERSE REACTIONS (UNDESIRABLE EFFECTS)). PRES is a rare neurologic disorder that can present with the following signs and symptoms including seizures, headache, altered

mental status, visual disturbance, or cortical blindness, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). In patients developing PRES, treatment of specific symptoms including control of hypertension is recommended, along with discontinuation of ZEJULA. The safety of reinitiating niraparib therapy in patients previously experiencing PRES is not known.

Pregnancy/contraception

ZEJULA should not be used during pregnancy or in women of childbearing potential not willing to use highly effective contraception during therapy and for 6 months after receiving the last dose of ZEJULA (see Section 4.6 FERTILITY, PREGNANCY AND LACTATION). A pregnancy test should be performed on all women of childbearing potential prior to treatment.

Lactose

ZEJULA capsules contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Tartrazine

This medicinal product contains tartrazine, which may cause allergic reactions.

Use in the elderly

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Paediatric use

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Pharmacodynamic interactions

The combination of ZEJULA with vaccines or immunosuppressant agents has not been studied.

The data on ZEJULA in combination with cytotoxic medicinal products are limited. Therefore, caution should be taken if ZEJULA is used in combination with vaccines, immunosuppressant agents or with other cytotoxic medicinal products.

Pharmacokinetic interactions

No clinical drug interaction studies have been performed with niraparib.

Effect of other medicinal products on niraparib

Niraparib as a substrate of CYPs (CYP1A2 and CYP3A4)

Niraparib is a substrate of carboxylesterases (CEs) and UDP-glucuronosyltransferases (UGTs) *in vivo*. Oxidative metabolism of niraparib is minimal *in vivo*. No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit (e.g. itraconazole, ritonavir, and clarithromycin) or induce CYP enzymes (e.g. rifampin, carbamazepine, and phenytoin).

Niraparib as a substrate of efflux transporters (P-gp, BCRP, and MATE1/2)

Niraparib is a substrate of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). However, due to its high permeability and bioavailability, the risk of clinically relevant interactions with medicinal products that inhibit these transporters is unlikely. Therefore, no dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit P-gp (e.g. amiodarone, verapamil) or BCRP (e.g. osimertinib, velpatasvir, and eltrombopag).

Niraparib is not a substrate of bile salt export pump (BSEP). The major primary metabolite M1 is not a substrate of P-gp, BCRP, or BSEP. Niraparib is not a substrate of MATE 1 or 2, while M1 is a substrate of both.

Niraparib as a substrate of hepatic uptake transporters (OATP1B1, OATP1B3, and OCT1)

Neither niraparib nor M1 is a substrate of organic anion transport polypeptide 1B1 (OATP1B1), 1B3 (OATP1B3), or organic cation transporter 1 (OCT1). No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit OATP1B1 or 1B3 (e.g. gemfibrozil, ritonavir), or OCT1 (e.g. dolutegravir) uptake transporters.

Niraparib as a substrate of renal uptake transporters (OAT1, OAT3, and OCT2)

Neither niraparib nor M1 is a substrate of organic anion transporter 1 (OAT1), 3 (OAT3), and organic cation transporter 2 (OCT2). No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit OAT1 (e.g. probenecid) or OAT3 (e.g. probenecid, diclofenac), or OCT2 (e.g. cimetidine, quinidine) uptake transporters.

Effect of niraparib on other medicinal products

Inhibition of CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5)

In vitro, neither niraparib nor its inactive major metabolite M1 is a clinically relevant inhibitor of any active substance-metabolising CYP enzymes, namely CYP1A1/2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.

Induction of CYPs (CYP1A2 and CYP3A4/5)

Neither niraparib nor M1 is a clinically relevant CYP3A4/5 inducer *in vitro*. *In vitro*, niraparib weakly induces CYP1A2 at high concentrations and the clinical relevance of this effect cannot be completely ruled out. M1 is not a CYP1A2 inducer. Therefore, caution is recommended when niraparib is combined with active substances the metabolism of which is CYP1A2-dependent and, notably, those having a narrow therapeutic range (e.g. clozapine, theophylline, and ropinirole).

Inhibition of efflux transporters (P-gp, BCRP, BSEP, MRP2 and MATE1/2K)

Neither niraparib nor M1 is a clinically relevant inhibitor of P-gp, BSEP or MRP2 and may be a weak BCRP inhibitor based on *in vitro* data and/or physiologically based pharmacokinetic (PBPK) modelling.

Niraparib is an inhibitor of MATE1/2K with IC₅₀ of 0.18 µM and ≤0.14 µM, respectively. M1 does not inhibit MATE1/2K. Simulations using PBPK modelling indicate an expected > 2-fold increase in exposure of metformin when administered with niraparib at 200 mg or 300 mg daily. Close monitoring of glycaemia is recommended when starting or stopping niraparib in patients receiving metformin. A dose adjustment of metformin may be necessary.

Inhibition of uptake transporters (OATP1B1, OATP1B3, OCT1, OAT1, OAT3 and OCT2)

Neither niraparib nor M1 is an inhibitor of hepatic uptake transporters OATP1B1 or OATP1B3 and renal uptake transporters OAT1, OAT3 or OCT2 *in vitro*.

In vitro, niraparib inhibits hepatic uptake transporter OCT1 with an $IC_{50} = 34.4 \mu M$ and an interaction is considered possible.

All clinical studies have only been performed in adults.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no clinical data on fertility. While no direct fertility studies were conducted in animals, repeat-dose toxicity studies in rats and dogs showed decreased spermatogenesis, small testes and germ cell depletion in the testes and epididymides at niraparib doses of 20 mg/kg/day and 6 mg/kg/day (0.74- and 0.05-times clinical exposure based on AUC, respectively). There was a trend towards reversibility of these findings 2-4 weeks after dosing was stopped.

Use in pregnancy (Category D)

There are no or a limited amount of data from the use of ZEJULA in pregnant women. Animal reproductive and developmental toxicity studies have not been conducted. However, based on its mechanism of action, ZEJULA could cause embryonic or fetal harm, including embryo-lethal and teratogenic effects, when administered to a pregnant woman. ZEJULA should not be used during pregnancy.

Women of childbearing potential should not become pregnant while on treatment and should not be pregnant at the beginning of treatment. A pregnancy test should be performed on all women of childbearing potential prior to treatment. Women of childbearing potential must use highly effective contraception during therapy and for 6 months after receiving the last dose of ZEJULA.

Use in lactation

It is unknown whether niraparib or its metabolites are excreted in human milk. Breast-feeding is contraindicated during administration of ZEJULA and for 1 month after receiving the last dose (see Section 4.3 CONTRAINDICATIONS).

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

ZEJULA may influence the ability to drive or use machines. Patients who take ZEJULA may experience asthenia, fatigue, difficulty concentrating and dizziness. Patients who experience these symptoms should observe caution when driving or using machines.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Tabulated list of adverse reactions

The following adverse reactions have been identified based on pooled data generated from the PRIMA and NOVA clinical trials in patients receiving ZEJULA monotherapy and during post-marketing experience (see Table 4).

Frequencies of occurrence of undesirable effects are defined as: very common $\geq 1/10$; common $\geq 1/100$ to $< 1/10$; uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Table 4: Tabulated list of adverse reactions^a

| System Organ Class | Frequency of all CTCAE^b grades | Frequency of CTCAE grade 3 or 4^b |
|--|--|--|
| Infections and infestations | Very common Urinary tract infection Common Bronchitis, conjunctivitis | Uncommon Urinary tract infection, bronchitis |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | Common Myelodysplastic syndrome/ acute myeloid leukaemia | Common Myelodysplastic syndrome/ acute myeloid leukaemia |
| Blood and lymphatic system disorders | Very common Thrombocytopenia, anaemia, neutropenia, leukopenia Common Neutropenic infection Uncommon Pancytopenia, febrile neutropenia, neutropenic sepsis | Very common Thrombocytopenia, anaemia, neutropenia Common Leukopenia Uncommon Neutropenic infection, febrile neutropenia, neutropenic sepsis, pancytopenia |
| Immune system disorders | Common Hypersensitivity (including anaphylaxis) | Uncommon Hypersensitivity (including anaphylaxis) |
| Metabolism and nutrition disorders | Very common Decreased appetite Common Hypokalaemia | Common Hypokalaemia Uncommon Decreased appetite |
| Psychiatric disorders | Very common Insomnia Common Anxiety, depression, cognitive impairment (memory impairment, concentration impairment) Uncommon Confusional state/disorientation, hallucination | Uncommon Insomnia, anxiety, depression, confusional state/disorientation, hallucination |

| System Organ Class | Frequency of all CTCAE^b grades | Frequency of CTCAE grade 3 or 4^b |
|---|---|---|
| Nervous system disorders | Very common Headache, dizziness Common Dysgeusia Rare Posterior Reversible Encephalopathy Syndrome (PRES)** | Uncommon Headache Rare Posterior Reversible Encephalopathy Syndrome (PRES)** |
| Cardiac disorders | Very common Palpitations Common Tachycardia | |
| Vascular disorders | Very common Hypertension Rare Hypertensive crisis | Common Hypertension Rare Hypertensive crisis |
| Respiratory, thoracic and mediastinal disorders | Very common Dyspnoea, cough, nasopharyngitis Common Epistaxis Uncommon Non-infectious pneumonitis | Uncommon Dyspnoea, epistaxis, non-infectious pneumonitis |
| Gastrointestinal disorders | Very common Nausea, constipation, vomiting, abdominal pain, diarrhoea, dyspepsia Common Dry mouth, mucositis, stomatitis | Common Nausea, vomiting, abdominal pain Uncommon Diarrhoea, constipation, mucositis, stomatitis, dry mouth |
| Skin and subcutaneous tissue disorders | Common Photosensitivity, rash | Uncommon Photosensitivity, rash |
| Musculoskeletal and connective tissue disorders | Very common Back pain, arthralgia Common Myalgia | Uncommon Back pain, arthralgia, myalgia |

| System Organ Class | Frequency of all CTCAE ^b grades | Frequency of CTCAE grade 3 or 4 ^b |
|--|---|--|
| General disorders and administration site conditions | Very common Fatigue, asthenia Common Oedema peripheral | Common Fatigue, asthenia |
| Investigations | Common Gamma-glutamyl transferase increased, AST increased, blood creatinine increased, ALT increased, blood alkaline phosphatase increased, weight decreased | Common Gamma-glutamyl transferase increased, ALT increased Uncommon AST increased, blood alkaline phosphatase increased |

^aFrequency based on niraparib clinical trial data not limited to pivotal PRIMA or NOVA monotherapy studies.

^bCTCAE=Common Terminology Criteria for Adverse Events version 4.02

Patients Receiving ZEJULA with Dose Based on Baseline Weight or Platelet Count in PRIMA:

Results for commonly reported events for patients receiving a 300 mg fixed starting dose or a 200 – 300 mg individualised starting dose based on baseline weight or platelet count, are summarised in Table 5. Commonly reported Grade ≥3 events are summarised in Table 6.

The adverse reactions noted in the group of patients who were administered a 200-mg starting dose of niraparib based on baseline weight or platelet count were of similar or lesser frequency compared to the group administered 300 mg. See Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE for specific information regarding frequency of thrombocytopenia, anaemia and neutropenia.

In general, the individualised starting dose decreased the incidence of myelosuppression events including anaemia (71% vs 50%) and thrombocytopenia (52% vs 34%) as compared to the fixed starting dose.

Table 5. Treatment Emergent Adverse Reactions Reported in ≥10% of Patients Receiving ZEJULA in PRIMA by Fixed or Individualised Starting Dose

| MedDRA Preferred Term (Grade 1-4) ^c | Fixed ^a | | Individualised ^b | |
|---|--------------------------|---------------------------|-----------------------------|--------------------------|
| | ZEJULA (n = 315) % | Placebo (n = 158) % | ZEJULA (n = 169) % | Placebo (n = 86) % |
| Blood and lymphatic system disorders | | | | |
| Thrombocytopenia | 52 | 4 | 34 | 4 |
| Anaemia | 71 | 12 | 50 | 28 |
| Neutropenia ^d | 28 | 6 | 24 | 7 |
| Leukopenia ^e | 12 | 5 | 12 | 6 |
| Gastrointestinal disorders | | | | |
| Nausea | 60 | 31 | 53 | 21 |
| Constipation | 43 | 21 | 31 | 15 |

| MedDRA Preferred Term (Grade 1-4) ^c | Fixed ^a | | Individualised ^b | |
|---|--------------------------|---------------------------|-----------------------------|--------------------------|
| | ZEJULA (n = 315) % | Placebo (n = 158) % | ZEJULA (n = 169) % | Placebo (n = 86) % |
| Vomiting | 25 | 13 | 17 | 9 |
| General disorders and administration site conditions | | | | |
| Fatigue | 36 | 29 | 33 | 30 |
| Metabolism and nutrition disorders | | | | |
| Decreased appetite | 19 | 10 | 19 | 5 |
| Musculoskeletal and connective tissue disorders | | | | |
| Arthralgia | 18 | 18 | 17 | 21 |
| Back Pain | 15 | 10 | 10 | 11 |
| Nervous system disorders | | | | |
| Headache | 28 | 13 | 22 | 17 |
| Dizziness | 17 | 11 | 11 | 11 |
| Psychiatric disorders | | | | |
| Insomnia | 27 | 15 | 21 | 14 |
| Respiratory, thoracic, and mediastinal disorders | | | | |
| Dyspnea | 19 | 13 | 16 | 11 |
| Cough | 15 | 14 | 0 | 0.4 |
| Vascular disorders | | | | |
| Hypertension | 18 | 6 | 16 | 9 |
| Investigations | | | | |
| AST increased | 10 | 4 | 7 | 5 |

MedDRA= Medical Dictionary for Regulatory Activities; AST = aspartate aminotransferase

^a Patients received a fixed starting dose of 300 mg prior to PRIMA protocol amendment.

^b Individualised starting dose: 200 mg in patients with body weight <77 kg or platelet count <150,000/ μ L or 300 mg in patients with body weight \geq 77 kg and platelet count \geq 150,000/ μ L.

^c All TEAEs in the table consist of grouped preferred terms except for nausea, vomiting, decreased appetite, headache, and insomnia, which are single preferred terms.

^d Includes neutropenia, neutropenic infection, neutropenic sepsis, and febrile neutropenia.

^e Includes leukopenia, lymphocyte count decreased, lymphopenia, and white blood cell count decreased.

Table 6. Grade 3 or 4 Treatment Emergent Adverse Reactions Reported in ≥5% of Patients Receiving ZEJULA in PRIMA by Fixed or Individualised Starting Dose

| MedDRA Preferred Term (Grade 3-4) ^c | Fixed ^a | | Individualised ^b | |
|---|--------------------------|---------------------------|-----------------------------|--------------------------|
| | ZEJULA (n = 315) % | Placebo (n = 158) % | ZEJULA (n = 169) % | Placebo (n = 86) % |
| Blood and lymphatic system disorders | | | | |
| Thrombocytopenia | 36 | 0 | 15 | 1 |
| Anaemia | 36 | 2 | 23 | 1 |
| Platelet count decreased | 16 | 0 | 7 | 0 |
| Neutropenia ^d | 15 | 1 | 10 | 1 |
| Neutrophil count decreased | 9 | 0 | 5 | 0 |
| Vascular disorders | | | | |
| Hypertension | 6 | 1 | 5 | 2 |

MedDRA= Medical Dictionary for Regulatory Activities; AST = aspartate aminotransferase

^a Patients received a fixed starting dose of 300 mg prior to PRIMA protocol amendment.

^b Individualised starting dose: 200 mg in patients with body weight <77 kg or platelet count <150,000/μL or 300 mg in patients with body weight ≥77 kg and platelet count ≥150,000/μL.

^c All TEAEs in the table consist of grouped preferred terms except for nausea, vomiting, decreased appetite, headache, and insomnia, which are single preferred terms.

^d Includes neutropenia, neutropenic infection, neutropenic sepsis, and febrile neutropenia.

Description of selected adverse reactions

Haematological adverse reactions (thrombocytopenia, anaemia, neutropenia), including clinical diagnoses and/or laboratory findings generally occurred early during ZEJULA treatment with the incidence decreasing over time.

In the clinical programme, haematological adverse reactions were managed with laboratory monitoring and dose modifications (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Thrombocytopenia

In the PRIMA safety population (n = 484), 39% of ZEJULA-treated patients experienced Grade 3-4 thrombocytopenia compared to 0.4% of placebo-treated patients with a median time from first dose to first onset in the ZEJULA arm of 22 days (range: 15 to 335 days) and with a median duration of 6 days (range: 1 to 374 days). Discontinuation due to thrombocytopenia occurred in 4% of patients.

In the NOVA study, approximately 60% of patients receiving ZEJULA experienced thrombocytopenia of any grade, and 34% of patients experienced Grade 3/4 thrombocytopenia. In patients with baseline platelet count less than 180,000 cells/μL, thrombocytopenia of any grade and Grade 3/4 occurred in 76% and 45% of the patients, respectively. The median time to onset of thrombocytopenia regardless of grade, and Grade 3/4 thrombocytopenia was 22 and 23 days, respectively. The rate of new incidences of thrombocytopenia after intensive dose modifications were performed during the first two months of treatment from Cycle 4 was 1.2%. The median duration of thrombocytopenia events of any grade was 23 days, and the median duration of Grade 3/4 thrombocytopenia was 10 days. Patients treated with

ZEJULA who develop thrombocytopenia might have an increased risk of haemorrhage. Discontinuation due to thrombocytopenia events (thrombocytopenia and platelet count decreased) occurred in approximately 3% of the patients.

In the NOVA study, 48 of 367 (13 %) patients experienced bleeding with concurrent thrombocytopenia; all bleeding events concurrent with thrombocytopenia were Grade 1 or 2 in severity except for one event of Grade 3 petechiae and haematoma observed concurrently with a serious adverse event of pancytopenia. Thrombocytopenia occurred more commonly in patients whose baseline platelet count was less than 180,000 cells/ μ L. Approximately 76 % of patients with lower baseline platelets (< 180,000 cells/ μ L) who received niraparib experienced thrombocytopenia of any grade, and 45 % of the patients experienced Grade 3/4 thrombocytopenia. Pancytopenia has been observed in < 1 % of patients receiving niraparib.

Anaemia

In the PRIMA safety population (n = 484), 31% of niraparib-treated patients experienced Grade 3/4 anaemia compared to 2% of placebo-treated patients with a median time from first dose to first onset in the niraparib arm of 80 days (range: 15 to 533 days) and with a median duration of 7 days (range: 1 to 119 days). Discontinuation due to anaemia occurred in 2% of patients.

In the NOVA study, approximately 50% of patients experienced anaemia of any grade, and 25% experienced Grade 3/4 anaemia. The median time to onset of anaemia of any grade was 42 days, and 85 days for Grade 3/4 events. The median duration of anaemia of any grade was 63 days, and 8 days for Grade 3/4 events. Anaemia of any grade might persist during ZEPJULA treatment. In the clinical programme, anaemia was managed with laboratory monitoring, dose modification (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION), and, where appropriate, with red blood cell transfusions. Discontinuation due to anaemia occurred in 1% of patients.

Neutropenia

In the PRIMA safety population (n = 484), 21% of niraparib-treated patients experienced Grade 3-4 neutropenia compared to 1% of placebo-treated patients with a median time from first dose to first onset in the ZEPJULA arm of 29 days (range: 15 to 421 days) and with a median duration of 8 days (range: 1 to 42 days). Discontinuation due to neutropenia occurred in 2% of patients.

In the NOVA study, approximately 30% of patients receiving ZEPJULA experienced neutropenia of any grade, and 20% of patients experienced Grade 3/4 neutropenia. The median time to onset of neutropenia of any grade was 27 days, and 29 days for Grade 3/4 events. The median duration of neutropenia of any grade was 26 days, and 13 days for Grade 3/4 events. In the clinical programme, neutropenia was managed with laboratory monitoring and dose modifications (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION). In addition, Granulocyte-Colony Stimulating Factor (G-CSF) was administered to approximately 6% of patients treated with ZEPJULA as concomitant therapy for neutropenia. Discontinuation due to neutropenia events occurred in 2% of patients.

Myelodysplastic syndrome/Acute myeloid leukaemia

In clinical studies, MDS/AML occurred in 1% patients treated with niraparib, with 41% of cases having a fatal outcome. The incidence was higher in patients with relapsed ovarian cancer who had received 2 or more lines of prior platinum chemotherapy and with gBRCAmut following 5.6 years survival follow-up. All patients had potential contributing factors for the development of MDS/AML, having received previous chemotherapy with platinum agents. Many had also received other DNA damaging agents and radiotherapy. The majority of reports were in gBRCAmut carriers. Some of the patients had a history of previous cancer or of bone marrow suppression.

In the PRIMA study, the overall incidence of MDS/AML was 2.3% in patients receiving niraparib and 1.6% in patients received placebo with a follow-up of 6.2 years.

In the NOVA study in patients with relapsed ovarian cancer who had received at least two prior lines of platinum chemotherapy, the overall incidence of MDS/AML was 3.5% in patients receiving niraparib and 1.7% in patients receiving placebo with a follow-up of 5.6 years. In gBRCAmut and non-gBRCAmut cohorts, the incidence of MDS/AML was 6.6% and 1.7% in patients receiving niraparib and 3.1% and 0.9% in patients receiving placebo, respectively.

Hypertension

In the PRIMA study, Grade 3-4 hypertension occurred in 6% of niraparib-treated patients compared to 1% of placebo-treated patients with a median time from first dose to first onset in the ZEJULA arm of 50 days (range: 1 to 589 days) and with a median duration of 12 days (range: 1 to 61 days). No patients discontinued ZEJULA due to hypertension.

Hypertension, including hypertensive crisis, has been reported with ZEJULA therapy.

In the NOVA study, hypertension of any grade occurred in 19.3% of patients treated with ZEJULA. Grade 3/4 hypertension occurred in 8.2% of patients. Discontinuation due to hypertension occurred in < 1% of patients.

Post-marketing data

Adverse reactions are listed below by system organ class and frequency.

| System Organ Class | Adverse reaction(s) | Frequency |
|-----------------------------|----------------------------|------------------|
| Renal and urinary disorders | Renal impairment | Unknown |
| | Acute kidney injury | Unknown |

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

There is no specific treatment in the event of ZEJULA overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should provide general supportive measures and should treat symptomatically.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

ATC Code

L01XK02

Mechanism of action

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumour cell lines with or without deficiencies in the BRCA1 and 2 tumour suppressor genes. In orthotopic high-grade serous ovarian cancer patient derived xenograft tumours (PDX) grown in mice, niraparib has been shown to reduce tumour growth in BRCA1 and 2 mutant, BRCA wild-type but homologous recombination (HR) deficient, and in tumours that are BRCA wild-type and without detectable HR deficiency.

Clinical trials

First-line ovarian cancer maintenance treatment

PRIMA was a double-blind, placebo-controlled trial in which patients (n=733) in complete or partial response to first-line platinum-based chemotherapy were randomised 2:1 to niraparib or matched placebo.

Patients were randomised post-completion of first-line platinum-based chemotherapy plus/minus surgery. Bevacizumab was allowed with chemotherapy. Patients who had neoadjuvant chemotherapy followed by interval debulking surgery could have visible residual or no residual disease. Randomisation was stratified by best response during the front-line platinum regimen (complete response vs partial response), neoadjuvant chemotherapy (NACT) (Yes vs No), and homologous recombination deficiency (HRD) status [positive vs negative or not determined]. Testing for HRD was performed using the HRD test on tumour tissue obtained at the time of initial diagnosis.

PRIMA was initiated with a starting dose of 300 mg once daily in continuous 28-day cycles (henceforth referred to as a fixed starting dose or FSD). Based on retrospective analyses of the NOVA trial, the starting dose in PRIMA was changed with Amendment 2 of the Protocol. From that point forward, patients with a baseline body weight ≥ 77 kg and baseline platelet count $\geq 150,000/\mu\text{L}$ were administered niraparib 300 mg (3 \times 100 mg capsules) or placebo (3 capsules) daily and patients with a baseline body weight < 77 kg or baseline platelet count $< 150,000/\mu\text{L}$ were administered ZEJULA 200 mg (2 \times 100 mg capsules) or placebo (2 capsules) daily (henceforth referred to as an individualised starting dose or ISD).

Patients began treatment on Cycle 1/Day 1 (C1/D1) with niraparib 200 or 300 mg or matched placebo administered once daily in continuous 28-day cycles. In the PRIMA study, 52 % of patients had a dose interruption in Cycle 1, 9% of patients in Cycle 1 and 47% of patients in Cycle 2 had a dose reduction.

Overall, the median dose intensity in subjects who received niraparib was 181.3 mg/day and the median relative dose intensity was 63% in subjects who received niraparib. In patients who received the individualised starting dose, the median dose intensity was 178.6 mg/day and the median relative dose intensity was 66%. In patients who received the fixed starting dose, the median dose intensity was 181.8 mg/day and the median relative dose intensity was 61%.

The major efficacy outcome measure, progression-free survival (PFS), was determined by blinded independent central review (BICR) per RECIST, version 1.1. PFS testing was performed hierarchically: first in the HR-deficient (HRd) population, then in the overall population. Overall survival (OS) was a key secondary endpoint. The median age was 62 and ranged from 32 to 85 years among patients randomised to niraparib and 33 to 88 years among patients randomised to placebo. Eighty-nine percent of all patients were white. Sixty-nine percent of patients randomised with niraparib and 71% of patients randomised with placebo had an Eastern Cooperative Oncology Group (ECOG) performance status of

0 at study baseline. In the overall population, 65% of patients had stage III disease, 35% had stage IV disease and the proportions of patients by primary tumour were as follows: ovarian (80.4%), primary peritoneal (6.4%) and fallopian (13.2%). Most patients (95.5%) had serous tumours and 2.3% of patients had an endometrioid tumour. Sixty-seven percent of the patients received NACT. Sixty-nine percent of the patients had a complete response to the first-line platinum-based chemotherapy.

In the PRIMA study bevacizumab was received by 6 (1.2%) patients in niraparib arm and 1 (0.4) in placebo group. Subjects who had received bevacizumab with their first-line platinum-based therapy but were unable to receive bevacizumab as maintenance therapy due to AEs or for any other reason, were deemed eligible to enter the PRIMA study.

PRIMA demonstrated a statistically significant improvement in PFS for patients randomised to niraparib as compared with placebo in the HR deficient and overall population (Table 7 and Figures 1 and 2).

Table 7: Progression-free survival efficacy results – PRIMA

| | HR-deficient population | | Overall population | |
|--|-------------------------|--------------------|----------------------|--------------------|
| | niraparib (N=247) | placebo (N=126) | niraparib (N=487) | placebo (N=246) |
| PFS median months(95% CI) ^b | 21.9 (19.3, NE) | 10.4 (8.1, 12.1) | 13.8 (11.5, 14.9) | 8.2 (7.3, 8.5) |
| p-value ^b | <0.0001 | | <0.0001 | |
| Hazard ratio (HR) ^c (95% CI) | 0.43 (0.31, 0.59) | | 0.62 (0.50, 0.76) | |

CI = confidence interval, PFS = progression-free survival, NE = not evaluable

^a Efficacy analysis was based on blinded independent central review (BICR).

^b Based on a stratified log-rank test

^c Based on a stratified Cox proportional hazards model

PFS= progression-free survival, CI= confidence interval

In patients who were administered 200 or 300 mg dose of niraparib based on baseline weight or platelet count, comparable efficacy was observed with a hazard ratio of 0.39 (95% CI [0.22, 0.72]) in the HR deficient population, and with a hazard ratio of 0.69 (95% CI [0.48, 0.98]) in the overall population. Efficacy in this individualised dosing regimen was also maintained in the HRd population with hazard ratio of 0.70 (95% CI [0.40 to 1.23]).

Figure 1: Progression-free survival in the patients with HR-deficient population- PRIMA (ITT population, N = 373)





Figure 2: Progression-free survival in the overall population- PRIMA (ITT population, N=733)




Within the HR deficient population, a PFS hazard ratio of 0.40 (95% CI: 0.27, 0.62) was observed in the subgroup of patients with *BRCAmut* ovarian cancer (n = 223). In the subgroup of HR-deficient patients without a *BRCA* mutation (n = 150), a hazard ratio of 0.50 (95% CI: 0.31, 0.83) was observed. In the HR proficient (HRD negative) population (n= 249), a hazard ratio of 0.68 (95% CI: 0.49, 0.94) was observed.

Overall survival analysis in PRIMA

At the final analysis of OS, the median OS in the overall population was 46.6 months (95% CI: 43.7, 52.8) for patients randomised to niraparib compared with 48.8 months (95% CI: 43.1, 61.0) in the placebo arm, with a hazard ratio of 1.01 (95% CI: 0.84, 1.23) (Figure 3). The maturity of the OS data for the overall population was 62.5%.

The median OS in the HR-deficient population was 71.9 months (95% CI: 55.5, NE) for patients randomised to niraparib compared to 69.8 months (95% CI: 51.6, NE) in the placebo arm, with a hazard ratio of 0.95 (95% CI: 0.70, 1.29) (Figure 4). The maturity of the OS data for the HR-deficient group was 49.6%.

Figure 3: Overall survival in the overall population – PRIMA (ITT population, N = 733)



Overall survival analysis – additional subgroup results in PRIMA

The median OS in the HR-proficient population (N = 249) was 36.6 months (95% CI: 31.7, 43.7) for patients randomised to niraparib compared to 32.2 months (95% CI: 26.3, 43.8) in the placebo arm, with a hazard ratio of 0.93 (95% CI: 0.69, 1.26) (Figure 5).

Recurrent ovarian cancer maintenance treatment

The safety and efficacy of niraparib as maintenance therapy was studied in a Phase 3 randomised, double-blind, placebo-controlled international trial (NOVA) in patients with relapsed predominantly high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who were platinum sensitive, defined by complete response (CR) or partial response (PR) for more than six months to their penultimate (next to last) platinum-based therapy. To be eligible for niraparib treatment, the patient was required to be in response (CR or PR) following completion of last platinum-based chemotherapy. The CA-125 levels were required to be normal (or a > 90% decrease in CA-125 from baseline) following their last platinum treatment and be stable for at least 7 days. Patients should not have received prior PARP inhibitor (PARPi) therapy, including niraparib. Eligible patients were assigned to one of two cohorts based on the results of a germline *BRCA* (*gBRCA*) mutation test. Within each cohort, patients were randomised using a 2:1 allocation of niraparib and placebo. Patients were assigned to the *gBRCA*mut cohort based on blood samples for *gBRCA* analysis that were taken prior to randomisation. Testing for *gBRCA* mutation and HRD was performed using the HRD test on tumour tissue obtained at the time of initial diagnosis or at the time of recurrence.

Randomisation within each cohort was stratified by time to progression after the penultimate platinum therapy before study enrolment (6 to < 12 months and ≥ 12 months); use or not of bevacizumab in conjunction with the penultimate or last platinum regimen; and best response during the most recent platinum regimen (complete response and partial response).

Patients began treatment on Cycle 1/Day 1 (C1/D1) with niraparib 300 mg or matched placebo administered QD in continuous 28-day cycles. Clinic visits occurred each cycle (4 weeks ± 3 days).

In the NOVA study, 48% of patients had a dose interruption in Cycle 1. Approximately 47% of patients restarted at a reduced dose in Cycle 2.

The most commonly used dose in niraparib-treated patients in the NOVA study was 200 mg.

Progression-free survival was determined per RECIST (Response Evaluation Criteria in Solid Tumors, version 1.1) or clinical signs and symptoms and increased CA-125. PFS was measured from the time of randomisation (which occurred up to 8 weeks after completion of the chemotherapy regimen) to disease progression or death.

The primary efficacy analysis for PFS was determined by blinded central independent assessment and was prospectively defined and assessed for the gBRCAmut cohort and the non-gBRCAmut cohort separately.

Demographics, baseline disease characteristics, and prior treatment history were generally well balanced between the niraparib and placebo arms in the gBRCAmut (n = 203) and the non-gBRCAmut cohorts (n = 350). Median ages ranged from 57 to 63 years across treatments and cohorts. The primary tumour site in most patients (> 80%) within each cohort was the ovary; most patients (> 84%) had tumours with serous histology. A high proportion of patients in both treatment arms in both cohorts had received 3 or more prior lines of chemotherapy, including 49% and 34% of niraparib patients in the gBRCAmut and non-gBRCAmut cohorts, respectively. Most patients were age 18 to 64 years (78%), Caucasian (86%) and had an ECOG performance status of 0 (68%).

In the gBRCAmut cohort, the median number of treatment cycles was higher in the niraparib arm than the placebo arm (14 and 7 cycles, respectively). More patients in the niraparib group continued treatment for more than 12 months than patients in the placebo group (54.4% and 16.9% respectively).

In the overall non-gBRCAmut cohort, the median number of treatment cycles was higher in the niraparib arm than in the placebo arm (8 and 5 cycles, respectively). More patients in the niraparib group continued treatment for more than 12 months than patients in the placebo group (34.2% and 21.1%, respectively).

The study met its primary objective of statistically significantly improved PFS for niraparib maintenance monotherapy compared with placebo in the gBRCAmut cohort (HR 0.27; 95% CI* 0.173, 0.410; p < 0.0001) as well as in the overall non-gBRCAmut cohort (HR 0.45; 95% CI* 0.338, 0.607; p < 0.0001). Table 8 shows the results for the PFS primary endpoint for the primary efficacy populations (gBRCAmut cohort and the overall non-gBRCAmut cohort).

Table 8: Progression-free survival efficacy results - NOVA study

| | gBRCAmut cohort | | Non-gBRCAmut cohort | |
|---|-------------------------------|--------------------------|-------------------------------|--------------------------|
| | ZEJULA (N = 138) | placebo (N = 65) | ZEJULA (N = 234) | placebo (N = 116) |
| PFS median in months (95% CI*) | 21.0 (12.9, NE) | 5.5 (3.8, 7.2) | 9.3 (7.2, 11.2) | 3.9 (3.7, 5.5) |
| p-value | < 0.0001 | | < 0.0001 | |
| Hazard ratio (HR) (Nir:plac) (95% CI*) | 0.27 (0.173, 0.410) | | 0.45 (0.338, 0.607) | |

PFS= progression-free survival, * CI = confidence interval, NE= Not Evaluable.

Prior to unblinding of the study, tumours of patients were tested for the presence of HRD using an experimental HRD test, which evaluates three indirect measures of tumour genome instability: loss of heterozygosity, telomeric allelic imbalance (TAI), and large-scale state transitions. In the HRDpos group, the hazard ratio was 0.38 (95% CI, 0.243, 0.586; p < 0.0001). In the HRDneg group, the hazard

ratio was 0.58 (95% CI, 0.361, 0.922; $p = 0.0226$). The experimental test was not able to discriminate which patients would or would not benefit from niraparib maintenance therapy.

Figure 6: Progression-free survival in the *gBRCA*mut cohort based on IRC assessment– NOVA (ITT population, N = 203)





Figure 7: Progression-free survival in the non-*gBRCA*mut cohort overall based on IRC assessment- NOVA (ITT population, N = 350)



Overall survival analyses in NOVA

Overall survival analyses were secondary outcome measures in the NOVA study. At the final analysis of overall survival, the median OS in the *gBRCA*mut cohort ($n = 203$) was 40.9 months for patients treated with niraparib compared with 38.1 months for patients on placebo (HR=0.85; 95% CI: 0.61,

1.20). The cohort maturity for the gBRCAmut cohort was 76%. The median OS in the non-gBRCAmut cohort (n = 350) was 31.0 months for patients treated with niraparib compared with 34.8 months for patients on placebo (HR=1.06; 95% CI: 0.81, 1.37). The cohort maturity for the non-gBRCAmut cohort was 79%.

Patient-Reported Outcomes

Patient-reported outcome (PRO) data from validated survey tools (FOSI and EQ-5D) indicate that niraparib-treated patients reported no difference from placebo in measures associated with quality of life (QoL).

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Following a single-dose administration of 300 mg niraparib under fasting conditions, niraparib was measurable in plasma within 30 minutes and the mean peak plasma concentration (C_{max}) for niraparib was reached within 5 hours [range 508 - 875 ng/mL across studies]. Following multiple oral doses of niraparib from 30 mg to 400 mg once daily, accumulation of niraparib was approximately 2 to 3-fold.

The systemic exposures (C_{max} and AUC) to niraparib increased in a dose-proportional manner when the dose of niraparib increased from 30 mg to 400 mg. The absolute bioavailability of niraparib is approximately 73%, indicating minimal first pass effect.

Administration of niraparib (3 x 100 mg) with a high-fat high-calorie meal may result in a slight decrease in C_{max} (~20%) relative to administration of niraparib (3 x 100 mg) under fasted conditions. Food did not significantly affect the overall exposure of niraparib (AUC_T and AUC_∞).

The tablet and capsule formulations have been demonstrated to be bioequivalent. Following administration of either one 300 mg tablet or three 100 mg capsules of niraparib in 108 patients with solid tumours under fasting conditions, the 90% confidence intervals of the geometric mean ratios of tablet compared to capsules for C_{max} , AUC_{last} and AUC_∞ fell within the limits of bioequivalence (0.80 and 1.25).

When niraparib tablets were administered following a high-fat meal in patients with solid tumours, niraparib C_{max} and AUC_{inf} increased by 11% and 28%, respectively (compared to administration under fasted conditions). Changes of this magnitude are not expected to be clinically meaningful.

Distribution

Niraparib was moderately protein bound in human plasma (83.0%), mainly with serum albumin. In a population pharmacokinetic analysis of niraparib, the Vd/F was 1206 L in cancer patients, indicating extensive tissue distribution of niraparib.

Metabolism

Niraparib is metabolised primarily by carboxylesterases to form a major inactive metabolite, M1. In a mass balance study, M1 and M10 (the subsequently formed M1 glucuronides) were the major circulating metabolites.

Excretion

Following a single oral 300-mg dose of niraparib, the mean terminal half-life ($t_{1/2}$) of niraparib ranged from 44 to 54 hours (approximately 2 days) across studies. In a population pharmacokinetic analysis, the apparent total clearance (CL/F) of niraparib was 15.9 L/h in cancer patients.

Niraparib is eliminated primarily through the hepatobiliary and renal routes. Following an oral administration of a single 300-mg dose of [¹⁴C]-niraparib, on average 86.2% (range 71% to 91%) of the

dose was recovered in urine and faeces over 21 days. Radioactive recovery in the urine accounted for 47.5% (range 33.4% to 60.2%) and in the faeces for 38.8% (range 28.3% to 47.0%) of the dose. In pooled samples collected over 6 days, 40.0% of the dose was recovered in the urine primarily as metabolites and 31.6% of the dose was recovered in the faeces primarily as unchanged niraparib.

Special populations

Renal impairment

In the population pharmacokinetic analysis of data from clinical studies in patients, pre-existing mild ($\text{CLCr} < 90$ to ≥ 60 mL/min) and moderate ($\text{CLCr} < 60$ to ≥ 30 mL/min) renal impairment did not influence the clearance of niraparib. No patients with pre-existing severe renal impairment or end-stage renal disease undergoing haemodialysis were identified in clinical studies (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Hepatic impairment

In the population pharmacokinetic analysis of data from clinical studies in patients, pre-existing mild hepatic impairment did not influence the clearance of niraparib.

In a clinical study of cancer patients using NCI-ODWG criteria to classify the degree of hepatic impairment, niraparib AUCinf in patients with moderate hepatic impairment (n=8) was 1.56 (90% CI: 1.06 to 2.30) times the niraparib AUCinf in patients with normal hepatic function (n=9) following administration of a single 300 mg dose. Niraparib dose adjustment is recommended for patients with moderate hepatic impairment (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION). Moderate hepatic impairment did not have an effect on niraparib Cmax or on niraparib protein binding.

The pharmacokinetics of niraparib have not been assessed in patients with severe hepatic impairment (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Age, weight and race

Population pharmacokinetic analyses indicated that age, weight and race had no significant impact on the pharmacokinetics of niraparib.

Paediatric population

No studies have been conducted to investigate the pharmacokinetics of niraparib in paediatric patients.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Niraparib was not mutagenic in a bacterial reverse mutation assay (Ames) test but was clastogenic in an *in vitro* mammalian chromosomal aberration assay and in an *in vivo* rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of niraparib and indicates potential for genotoxicity in humans.

Carcinogenicity

Carcinogenicity studies have not been conducted with niraparib.

Animal pharmacology and toxicology

In vitro, niraparib inhibited dopamine (DAT) and norepinephrine (NET) transporters at concentration levels below anticipated human exposure levels (based on unbound C_{max}). In mice, single doses of niraparib increased intracellular levels of dopamine and metabolites in the cortex. Reduced locomotor

activity was seen in one of two single dose studies in mice. The clinical relevance of these findings is not known but effects on blood pressure and pulse rate that may be related to inhibition of these transporters have occurred in patients.

In repeat-dose oral toxicity studies, niraparib was administered daily for up to 3 months' duration in rats and dogs. The major primary target organ for toxicity in both species was the bone marrow, with associated changes in peripheral haematology parameters. Additionally, decreased spermatogenesis was seen in both species. These findings occurred at exposure levels below those seen clinically, and were largely reversible within 4 weeks of cessation of dosing in dogs but not rats.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Capsules

Capsule content:

lactose monohydrate, magnesium stearate

Capsule shell:

titanium dioxide, gelatin, brilliant blue FCF, erythrosine, tartrazine

Printing inks:

Black Ink; SW-9040 (PI:12418). White Ink; TekPrint SB-0007P White Ink (PI 2216).

Tablets

Tablet core:

Microcrystalline cellulose, Lactose monohydrate, Povidone, Crospovidone, Silicon dioxide, Magnesium stearate

Film coating:

Polyvinyl alcohol, Titanium dioxide, macrogol 4000, Purified talc, Ferrosoferric oxide

6.2 INCOMPATIBILITIES

Not applicable.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Capsules

Store below 25°C.

Tablets

Store below 30°C. Store in original container.

6.5 NATURE AND CONTENTS OF CONTAINER

Capsules are available in Aclar/PVC/aluminium foil perforated unit dose blisters in cartons of 28, 56, and 84 capsules.

Film-coated tablets are available either in oPA/aluminium/PVC/aluminium/vinyl/acrylic blisters or in oPA/aluminium/PVC/Paper layer/aluminium/vinyl/acrylic (child-resistant blisters) in cartons of 84 × 1 and 56 × 1 film-coated tablets.


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure

The chemical name for niraparib tosylate monohydrate is (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium 4-methylbenzenesulfonate monohydrate. The molecular formula is $C_{19}H_{20}N_4 \cdot OC_7H_8O_3S \cdot H_2O$ which corresponds to a formula weight of 510.61 g/mol. Niraparib tosylate monohydrate has one chiral centre of the S configuration. The chemical structure is shown below:



Niraparib tosylate monohydrate is a white to pale brown powder.

CAS number

1038915-60-4 (niraparib)

1613220-15-7 (niraparib tosylate monohydrate)

7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (Schedule 4)

8 SPONSOR

GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street,
Abbotsford, Victoria, 3067

Phone: 1800 033 109

www.gsk.com.au

9 DATE OF FIRST APPROVAL

28 June 2019

10 DATE OF REVISION

15 January 2026

Summary table of changes

| Section changed | Summary of new information |
|-------------------------|--|
| 4.2; 4.4; 4.8; 5.1; 5.2 | Editorial updates |
| 4.4; 4.8; 5.1 | Addition of final analysis results from PRIMA |
| 4.5 | Updated text relating to interactions, specifically on the effect of niraparib on other medicinal products |
| 5.2 | Updated pharmacokinetic information |
| 6.4 | Update to the storage conditions |
| 6.5 | Update to the description of the blister materials |

Version 10.0

Trade marks are owned by or licensed to the GSK group of companies.

© 2026 GSK group of companies or its licensor.